GlassScriptPhysician profile
Kenneth J Mcalpine
NPI 1659472918
$2,975.91
in general payments reported to CMS, 2019-2025
28 companies · $501 in 2025
The $501 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $237 · 2021: $469 · 2022: $280 · 2023: $291 · 2024: $513 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.67 |
| Education | $108.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.67 | 2019-2023 | |
| Astellas Pharma US INC | $587.12 | 2019-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $457.22 | 2019-2025 | Aptima, Novasure, Coolseal Generator |
| Conformis, INC. | $255.34 | 2019 | |
| Exeltis, USA INC. | $236.06 | 2025 | Slynd, Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $162.92 | 2019-2024 | |
| Coopersurgical, INC. | $82.45 | 2019-2021 | |
| Ethicon US, LLC | $78.03 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $57.83 | 2021-2022 | |
| Duchesnay USA Incorporated | $49.38 | 2019 | |
| Sumitomo Pharma America, INC. | $36.75 | 2023 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $35.88 | 2021-2022 | |
| Cgg Medical INC | $35.83 | 2025 | |
| Olympus America INC. | $33.36 | 2021-2022 | |
| Teleflex LLC | $24.76 | 2025 | Quikclot |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.35 | 2025 | Axonics |
| Amag Pharmaceuticals, INC. | $23.96 | 2019 | |
| Sanofi Pasteur INC. | $21.62 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $21.61 | 2023 | Exparel |
| Sage Therapeutics, LLC | $20.62 | 2024 | |
| Seqirus USA INC | $19.53 | 2021 | |
| Evofem Biosciences, INC. | $19.45 | 2021 | |
| Pfizer INC. | $18.94 | 2024 | |
| Organon LLC | $18.23 | 2025 | Jada System |
| Millicent US INC | $17.52 | 2024 | Femring, Intrarosa |
| Medtronic, INC. | $15.60 | 2021 | |
| Agile Therapeutics, INC. | $11.99 | 2021 | |
| Covidien LP | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mcalpine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.